000			01848 a2200505 4500
005			20250515200757.0
264		0	_c20100322
008			201003s 0 0 eng d
022			_a1759-4782
024	7		_a10.1038/nrclinonc.2009.187 _2doi
040			_aNLM _beng _cNLM
100	1		_aShepard, Dale R
245	0	0	_aInnovations in the systemic therapy of prostate cancer. _h[electronic resource]
260			_bNature reviews. Clinical oncology _cJan 2010
300			_a13-21 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAdenocarcinoma _xdrug therapy
650	0	4	_aAndrogen Antagonists _xadverse effects
650	0	4	_aAndrogens
650	0	4	_aAndrostenes
650	0	4	_aAndrostenols _xtherapeutic use
650	0	4	_aAntineoplastic Agents, Hormonal _xadverse effects
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aCardiovascular Diseases _xchemically induced
650	0	4	_aChemotherapy, Adjuvant
650	0	4	_aClinical Trials as Topic
650	0	4	_aCombined Modality Therapy
650	0	4	_aDisease Progression
650	0	4	_aDrug Delivery Systems
650	0	4	_aDrugs, Investigational _xadverse effects
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMulticenter Studies as Topic
650	0	4	_aNeoadjuvant Therapy
650	0	4	_aNeoplasm Proteins _xantagonists & inhibitors
650	0	4	_aNeoplasms, Hormone-Dependent _xdrug therapy
650	0	4	_aOsteoporosis _xchemically induced
650	0	4	_aProstatectomy
650	0	4	_aProstatic Neoplasms _xdrug therapy
650	0	4	_aSalvage Therapy
650	0	4	_aSurvival Analysis
700	1		_aRaghavan, Derek
773	0		_tNature reviews. Clinical oncology _gvol. 7 _gno. 1 _gp. 13-21
856	4	0	_uhttps://doi.org/10.1038/nrclinonc.2009.187 _zAvailable from publisher's website
999			_c19379523 _d19379523